14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
KALV vs SANA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KALV Overall Winner
6-Pillar Tally: KALV 3 – 2 SANA (1 Tie)
Matrix Metrics: KALV 7 – 3 SANA
As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KALV carries a Unified Composite Score of 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: KALV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KALV vs SANA. Trailing 12-month operating profitability (KALV -57.4% vs SANA 0.0%) and valuation multiples (KALV 25.4x vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and -57.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SANA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KALV vs SANA Key Questions & Quantitative Answers
As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KALV carries a Unified Composite Score of 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: KALV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KALV leads the Growth & Scale pillar: KALV posts +30.7% YoY revenue growth and +0.0% YoY earnings growth on $114M TTM revenue (51.1% gross margin, -57.4% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KALV generates $114M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, KALV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.
KALV screens cheaper on headline valuation multiples. KALV trades at 25.4x Forward P/E, 25.4x Trailing P/E, N/M PEG, and 12.6x EV/Revenue (-120.9% EBITDA margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KALV (-190.2% ROE) versus SANA (-79.5% ROE) capital efficiency.
In options market volatility and institutional positioning, KALV carries 88.9% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 26.28x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 2% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.